BRIEF published on 06/18/2025 at 07:05, 9 months 28 days ago PHAXIAM Therapeutics suspends trading of its shares Euronext Paris Innovative Treatments PHAXIAM Suspension Of Quotation Delisting Securities
PRESS RELEASE published on 06/18/2025 at 07:00, 9 months 28 days ago Inside Information / Other news releases PHAXIAM Therapeutics suspends trading shares for delisting on Euronext Paris market. No reimbursement to shareholders. Company focuses on innovative phage-based treatments for resistant bacterial infections Trading Delisting Suspension PHAXIAM Therapeutics Phage-based Treatments
BRIEF published on 06/05/2025 at 07:05, 10 months 11 days ago PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement Biopharmaceuticals Judicial Liquidation Court Hearing PHAXIAM Therapeutics Euronext Delisting
PRESS RELEASE published on 06/05/2025 at 07:00, 10 months 11 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces new postponement of Offer Review Hearing by Lyon Commercial Court to June 11, 2025. Company to request delisting from Euronext Euronext Delisting Postponement PHAXIAM Therapeutics Lyon Commercial Court
BRIEF published on 03/14/2025 at 17:50, 1 year 1 month ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
PRESS RELEASE published on 03/14/2025 at 17:45, 1 year 1 month ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
BRIEF published on 03/06/2025 at 18:01, 1 year 1 month ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year 1 month ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 1 year 1 month ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 12/30/2024 at 17:50, 1 year 3 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
Published on 04/17/2026 at 02:00, 9 minutes ago UraniumX Announces Closing Of Final Tranche Of Non-Brokered Private Placement
Published on 04/16/2026 at 23:32, 2 hours 37 minutes ago Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 4 hours 39 minutes ago Organto Foods Expands Financing Facilities with Rabobank
Published on 04/16/2026 at 15:20, 10 hours 49 minutes ago Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 2026
Published on 04/16/2026 at 23:40, 2 hours 29 minutes ago Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 4 hours 32 minutes ago Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 5 hours 9 minutes ago Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 5 hours 34 minutes ago EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 6 hours 51 minutes ago EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 18:02, 8 hours 7 minutes ago Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 17:54, 8 hours 15 minutes ago Aéroports de Paris S.A - March 2026 traffic figures
